HemaSure, Novo Nordisk deal

HMSR will form a subsidiary in Denmark to purchase Novo Nordisk's plasma pharmaceutical business for an undisclosed amount. The business unit generated revenues of $20 million in 1995.

The agreement is part of HMSR's strategy to expand its SteriPath pathogen inactivation technology into the plasma pharmaceutical manufacturing business. ...